AAA
Affinity Asset Advisors’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-9,992
| Closed | -$252K | – | 89 |
|
|
2024
Q4 | $252K | Sell |
9,992
-115,008
| -92% | -$2.91M | 0.03% | 68 |
|
|
2024
Q3 | $4.25M | Sell |
125,000
-350,400
| -74% | -$11.9M | 0.58% | 43 |
|
|
2024
Q2 | $17.6M | Sell |
475,400
-34,600
| -7% | -$1.28M | 2.03% | 9 |
|
|
2024
Q1 | $21.4M | Buy |
510,000
+110,000
| +28% | +$4.62M | 2.65% | 6 |
|
|
2023
Q4 | $15.9M | Buy |
400,000
+250,000
| +167% | +$9.92M | 2.9% | 11 |
|
|
2023
Q3 | $4.13M | Buy |
150,000
+62,969
| +72% | +$1.73M | 1.16% | 23 |
|
|
2023
Q2 | $2.95M | Buy |
87,031
+37,031
| +74% | +$1.26M | 1.03% | 28 |
|
|
2023
Q1 | $1.8M | Sell |
50,000
-60,000
| -55% | -$2.16M | 0.59% | 37 |
|
|
2022
Q4 | $4.9M | Buy |
110,000
+30,000
| +38% | +$1.34M | 1.92% | 17 |
|
|
2022
Q3 | $2.25M | Buy |
80,000
+40,000
| +100% | +$1.12M | 0.63% | 29 |
|
|
2022
Q2 | $1.08M | Sell |
40,000
-85,000
| -68% | -$2.29M | 0.45% | 28 |
|
|
2022
Q1 | $4.26M | Buy |
125,000
+25,000
| +25% | +$852K | 0.68% | 22 |
|
|
2021
Q4 | $3.86M | Buy |
100,000
+59,846
| +149% | +$2.31M | 1.4% | 25 |
|
|
2021
Q3 | $2.17M | Sell |
40,154
-9,846
| -20% | -$532K | 0.55% | 32 |
|
|
2021
Q2 | $1.67M | Sell |
50,000
-80,000
| -62% | -$2.68M | 0.6% | 33 |
|
|
2021
Q1 | $2.68M | Buy |
130,000
+55,000
| +73% | +$1.13M | 0.91% | 24 |
|
|
2020
Q4 | $1.31M | Buy |
+75,000
| New | +$1.31M | 0.7% | 32 |
|